Kayentis and RWS partner to improve clinical trial data confidence
pharmafile | April 17, 2026 | News story | Research and Development | RWS, kayentis
Kayentis and RWS have announced a partnership aimed at improving confidence in clinical trial data for neuroscience and other complex trials.
The collaboration combines Kayentis’ electronic Clinical Outcome Assessment (eCOA) platform with RWS’ rater training services, with a focus on reducing variability in clinician-reported outcomes. The companies said this is a key challenge in central nervous system (CNS) trials, where long study durations, complex assessment scales and vulnerable patient populations can affect data consistency.
Guillaume Juge, CEO of Kayentis, said: “Capturing data digitally isn’t enough, sponsors need data they can trust. By aligning rater qualification with purpose-built eCOA workflows, we help reduce variability and give teams greater confidence in their results.”
The joint approach aims to address inconsistencies in how clinicians apply scoring systems, which can affect endpoint reliability and overall trial validity. By integrating training, certification and data capture, the partners said the model supports more consistent assessments across trial sites and throughout the course of a study.
Their combined offering includes tailored rater training and ongoing monitoring, alongside eCOA tools designed for complex clinician-reported outcomes. It also incorporates access controls to ensure that only qualified clinicians complete specific assessments, reducing the risk of errors linked to untrained or uncertified raters.
Kayentis and RWS said the approach is intended to support sponsors and contract research organisations managing global trials, helping to reduce operational complexity while maintaining data quality. Their partnership builds on an existing collaboration between the two organisations and reflects recent investment in CNS-focused capabilities and digital trial infrastructure.
The solution is available for sponsors and CROs running CNS and other complex trials requiring high-quality clinician-reported outcomes (ClinRO) data, from study start through to close.
